Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
about
The Role of Immunotherapy in Multiple MyelomaComputational modeling of interactions between multiple myeloma and the bone microenvironmentChimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation.A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancerp38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.The therapeutic potential of interleukin-6 hyperagonists and antagonists.Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse modelMathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Iron increases the susceptibility of multiple myeloma cells to bortezomib.Modeling and experiments of magneto-nanosensors for diagnostics of radiation exposure and cancerA virtual approach to evaluate therapies for management of multiple myeloma induced bone diseaseInterleukin-6 as a therapeutic target in candidate inflammatory diseases.Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.Siltuximab: first global approval.Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.Siltuximab for multicentric Castleman disease.The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs.IL-6 promotes CD4+ T-cell and B-cell activation during Plasmodium infection.A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
P2860
Q26771144-9C92651C-DF8D-4E01-8525-E61011A9B3BDQ28477867-05668B08-B763-4A83-9487-71C00C976703Q33503487-939E04E7-7D2C-4333-986A-067721F4784AQ33851778-7FC63AF8-F6E5-4EF2-8890-32D6DB655B65Q34023737-EDCB9FAC-A5A5-4992-84E0-5A25216F4793Q34356907-97F54AD3-B84C-4CDD-9321-95D542124E50Q34430168-F514D88D-2FDD-474E-BCBD-42A663672EF9Q34742485-4F4788BE-79DC-49F0-99C4-FCC845782B47Q34806153-AE4278FD-96CF-459B-B9E1-49273149769FQ36892625-BC11862F-EEB9-4CE6-965F-75BF7F7CCC73Q36906688-F190501F-A0CD-4075-9CD1-A4D0AEA32714Q37185494-9FECD941-684B-469B-84A1-E109C1F6BAAAQ37698197-7CC3FF5D-276B-4C84-8253-67415E1582F9Q37901025-280B959B-6DAF-41A3-A6F9-D22B4DB101E5Q38222680-2BED7EB9-D033-46FF-8FA4-5ADE557266C8Q38855010-C5A23767-2229-4486-9495-32F5F4FFDC1FQ39146671-B55C433B-6BBB-45C5-A8DA-908F55AFF2B8Q39830126-6D0840B1-84A2-4EE9-BFF0-845CEB480F0FQ40117722-D676CACD-2F42-4B40-9DBB-021615499113Q40350326-298A095F-6DD2-432A-91B6-902623104AB3
P2860
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@en
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@nl
type
label
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@en
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@nl
prefLabel
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@en
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@nl
P2093
P2860
P921
P356
P1476
Endogenous interleukin 6 produ ...... of a positive feed-back loop.
@en
P2093
Koopmans RP
Lokhorst HM
Rensink HJ
Stouthard JM
Warnaar SO
van Oers MH
van Zaanen HC
P2860
P304
P356
10.1172/JCI118932
P407
P577
1996-09-01T00:00:00Z